Member Info for jmfw

🤞

Didn't appreciate Clovis are involved in the veterinary field.

FWIW

https://www.thetradenews.com/leaders-in-trading-2023-meet-the-nominees-for-outstanding-dark-trading-venue/

'old hat' I know, but this was posted on iWeb today:

https://www.markets.iweb-sharedealing.co.uk/research-centre/market-news/article/?id=14744278&type=bsm

Let's hope HCI have a ready made buyer for their quarterly unloading. It will be telling if their entitlement is offloaded without reaching the Market.

As with tipster. However, hci want their money, so they will continue to unload 'repayment' shares into the Market until, 1) repayment + interest is paid in cash, 2) an II picks up their unwanted, 3) they hold 'for gold' which is unlikely until they've satisfied the principal sum. AIM market is notorious, so until the data we are all waiting for is released, a 'fluid' sp is all we can expect (ofcourse,all imo). A great buying opportunity for the some of us.

Large seller will not run out. Has some £45m to sell,+ interest payments. But that does not deflect the science & potential, only current sp.

Very unwoke CJ.

Sp nothing to do with the unsecured convertible bond then?

How would a split impact our JV with Daewong, & licensing to LG? I.E. in what camp do the affimers sit?

Https://www.verywellhealth.com/definition-of-first-line-treatment-2249101

BV, extract from the rns "In addition to the excellent safety profile being observed for AVA6000, clear signs of efficacy have now been confirmed. One patient with soft tissue sarcoma has shown a significant reduction in tumour volume in response to the drug, with further signs of activity observed in patients WITH CANCERS NOT LIMITED TO SOFT TISSUE SARCOMA."

"Not surprising given the scandals that hit AIM shares every week"
Example today IBPO

Not sure I trust Cerone. He also runs Tiziana. Many s/h were left angry & deeply frustrated by the shenanigans that appeared to have perpetrated there prior to it moving to Nasdaq.

Heights will, presumably, sell their shares until the loan has been repaid. Once satisfied they may well review their options.

It works. It does what it's supposed to do, & that is improve the chemo by targeting the cancer. It's not a cure. The drug is the cure. Ava6000 allows many more doses with little toxicity. Ava3996 sounds even more promising. 'The Market' will, in the main, be ignorant about the tech, as I'm sure many Avacta investors are. So why should 'The Market' be knowledgeable? Those that will understand the tech will be the biotechs. Also, seems many 'investors' (on this bb at least) don't understand the trial process & purpose. So what chance has either 'Mr Market', or the media got?
Avacta will not reward understanding, but, it (likely) will patience.

Wyn, your 8.40. There are 3 positions, not 2. Also you mention 'on balance', but then suggest you're not fence sitting. If you're not on the fence, why is balance required?

Only one hospital in the list NOT 'recruiting'.

The strategy doesn't sit with how Myles understood Avacta was/is going to progress at this time
"continues to actively pursue other opportunities that add the other pieces of the jigsaw to build a fully integrated diagnostics business".
He was under the impression our funds were to be focused on TX.

Prof, whoever predicted £2 had the excuse of using, & speculating, on what was/is known about Avacta organically.
Chartists use historical sp movement only & don't need to know any detail about their target. So when a technical 'expert' contributes, they have nothing to add, other than encourage some who wish to trade. Think majority on this bb take a longer view of the company.